Albor Biologics

Albor Biologics is a private biotechnology company formed to commercialize intellectual property related to the leukocyte activation molecule CD69, reportedly licensed from researchers in Madrid. The company appears to have focused on developing biologic therapeutics, likely including anti-CD69 antibody approaches, for immune-mediated and inflammatory diseases. Public information on the company is sparse, and there is no clear evidence of an active clinical-stage pipeline or marketed products. Available business-directory and founder-biography references suggest the company remained a very small private entity with limited disclosed operations.